Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pandion Therapeutics Inc.

www.pandiontx.com

Latest From Pandion Therapeutics Inc.

Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet

Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds. 

Financing Business Strategies

Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned

A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.

Deals Financing

Scrip Asks…What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

Innovation Market Intelligence

Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers

Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Hepatic (Liver)
  • Immune Disorders
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Pandion Therapeutics Inc.
  • Senior Management
  • Rahul Kakkar, MD, CEO
    Jo Viney, PhD, Pres. & CSO
    Vikas Goyal, SVP, Bus. Dev.
  • Contact Info
  • Pandion Therapeutics Inc.
    Phone: (617) 393-5925
    610 Main St.
    Cambridge, MA 02139
    USA
UsernamePublicRestriction

Register